Why it Matters

BioWound Solutions LLC is expanding its lobbying firepower by adding the McManus Group to its advocacy efforts. The wound care company previously worked only with Michael Best Strategies LLC, but now has two firms working on Medicare reimbursement issues. This signals the company views policy battles as critical to its business success.

By the Numbers

BioWound Solutions has spent $240,000 on lobbying since January 2025 across 9 total filings. The company paid Michael Best Strategies $170,000 across 6 disclosures. The McManus Group received $70,000 across 3 filings, including $50,000 in Q2 2025.

Two lobbyists are working the account: John E. McManus, a former House Ways and Means Committee staffer, and Alex Whalen, who has lobbied for biotech companies like GRAIL Inc. and Zimmer Biomet Holdings Inc..

Broader Context

Congress is actively considering wound care legislation that could reshape the industry. The House Energy and Commerce Committee recently marked up safety legislation for human cell and tissue products. Meanwhile, members like Bill Cassidy, Young Kim, Gary Palmer, and Beth Van Duyne are publicly discussing medical innovation and patient access issues.

The Agenda

BioWound Solutions is lobbying on “Coverage and reimbursement for Human Cell & Tissue products.” The company is specifically targeting Local Coverage Determination L39764 regarding skin substitute grafts for diabetic foot ulcers and venous leg ulcers. This policy directly affects reimbursement for the company’s bio-ConneKt Wound Matrix product.

Competitive Landscape

Multiple companies are fighting similar policy battles. Acesso Biologics and VIVEX Biologics Inc. are also lobbying on L39764. Larger players like Organogenesis Inc. and Integra LifeSciences Corp. focus on broader Medicare policies. Industry group Medicare Access to Skin Substitutes Coalition coordinates advocacy efforts.

Between The Lines

Two key bills are moving through Congress that affect BioWound Solutions directly. S.2561 – Skin Substitute Access and Payment Reform Act of 2025 would reform Medicare’s payment structure for skin substitutes. H.R.340 – The HCT/P Modernization Act of 2025 aims to modernize regulatory oversight for human cell and tissue products. Both could significantly impact the company’s market access.

The Bottom Line

BioWound Solutions is making a calculated investment in Washington influence as Congress debates policies central to its business model. The addition of McManus Group brings Medicare expertise, but the company faces intense competition from well-funded rivals in a crowded lobbying field.